



Old drug, new findings: colistin resistance and dependence of *Acinetobacter baumannii*

Kwan Soo Ko, Yujin Choi, Ji-Young Lee

Department of Molecular Cell Biology, Sungkyunkwan University School of Medicine, Suwon, Korea

Received: August 30, 2017

Revised: October 23, 2017

Accepted: October 24, 2017

Corresponding author:

Kwan Soo Ko

Department of Molecular
Cell Biology, Sungkyunkwan
University School of Medicine,
2066 Seobu-ro, Jangan-gu,
Suwon 16419, Korea
Tel: +82-31-299-6223
E-mail: ksko@skku.edu

ABSTRACT

Colistin is an old drug, and its use has recently resurged because of increasing antibiotic resistance in gram-negative bacteria such as *Acinetobacter baumannii*. Although the colistin resistance rates in gram-negative bacteria are currently not high, many colistin-resistant isolates are being identified and the possibility of horizontal transmission of colistin resistance has increased because of the plasmid-borne colistin resistance gene *mcr-1* (mobilized colistin resistance). In this review, we have discussed colistin resistance in *A. baumannii*. In addition, we have reviewed an abnormal phenomenon called colistin dependence in *A. baumannii*.

Keywords: Gram-negative bacteria; PmrAB; Polymyxins

INTRODUCTION

Acinetobacter was most probably first described as *Diplococcus mucosus* in 1908. In 1954, Brissou and Prévot proposed the genus *Acinetobacter* to indicate that the bacteria were non-motile because they lacked flagella: the Greek “akineto” means “immobile” [1]. *Acinetobacter* spp. are glucose-non-fermentative, non-motile, non-fastidious, catalase-positive, oxidative-negative, aerobic, and gram-negative coccobacilli [2]. The genus *Acinetobacter* includes 55 species (as of July 18, 2017; <http://www.bacterio.net/acinetobacter.html>), and the number of species is increasing [3]. *Acinetobacter baumannii* is the most common species to cause infections, followed by *Acinetobacter nosocomialis* and *Acinetobacter pittii* [4,5]. *Acinetobacter lwoffii*, *Acinetobacter haemolyticus*, *Acinetobacter johnsonii*, *Acinetobacter junii*, *Acinetobacter ursingii*, *Acinetobacter schindleri*, *Acinetobacter calcoaceticus*, and *Acinetobacter seifertii* have occasionally been reported in humans [5,6]. *A. baumannii*, *A. calcoaceticus*, *A. nosocomialis*, and *A. pittii* have very similar biochemical traits and could be separated well; they were grouped into the so-called “*A. calcoaceticus*-*A. baumannii* (Acb) complex” [7]. *A. seifertii* is also closely related to the species of the Acb complex [8,9].

Acinetobacter spp., including *A. baumannii*, have long been known as colonizers in humans, but they do not cause severe infections [10]. However, *A. baumannii* causes infections in immunosuppressed patients, patients with serious underlying diseases, and those subjected to invasive procedures and treated with broad-spectrum antibiotics; it may be a pathogen that

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<http://creativecommons.org/licenses/by-nc/4.0/>).

has adapted the most to the hospital environment in the 21st century [11]. *A. baumannii* has become a representative pathogen that threatens human health. It is a member of the ESKAPE group, which is the main bacterial group that causes infections in humans [12], and has been recently ranked as a bacterium that poses the greatest health threat by World Health Organization [13]. In the United States, *A. baumannii* has been estimated to cause more than 2% of the health-care-associated infections [14]. *Acinetobacter* spp. are the seventh most-isolated bacteria in Korean hospitals [15], and they are the most frequent isolates from adults with hospital-acquired pneumonia or ventilator-associated pneumonia in Asian countries, including South Korea [16].

Although β -lactam antibiotics are the preferred choice for susceptible *A. baumannii* infections, carbapenems have become the main therapeutic option because of an increase in resistance [2,6]. However, imipenem-resistant isolates were found in the early 1990s [17], and the rate of carbapenem resistance in *A. baumannii*, mainly due to OXA-type (oxacillin-hydrolysing) carbapenemases, has increased rapidly [7,11]. In South Korea, more than two-thirds of the *A. baumannii* isolates were resistant to imipenem on the basis of several surveillance studies [4,15,18]. Most of the carbapenem-resistant *A. baumannii* isolates showed multidrug resistance (MDR) or extreme drug resistance (XDR), which is defined as resistance to all available antibiotics, except for one or two agents [19]. Current treatment options for XDRA *A. baumannii* infections remain quite limited. In addition to tigecycline, a recently developed antibiotic—an old drug, colistin—is often the last resort for treating XDRA *A. baumannii* [6,20].

COLISTIN

Polymyxin antibiotics include colistin (also known as polymyxin E), and polymyxin B is an antimicrobial polypeptide that was originally isolated in 1947 from the soil bacterium *Paenibacillus polymyxa* [21]. Colistin differs from polymyxin B by only one amino acid at position 6 in the peptide ring: a leucine in colistin and a phenylalanine in polymyxin B [22]. Although they have similar antimicrobial spectra and resistance mechanisms, the method for administration is different: while polymyxin B is administered directly in the active form, colistin is administered in the form of an inactive pro-drug, colistin methanesulphonate (also known as colistimethate [CMS]). CMS itself lacks antibacterial activity, but it is converted into colistin after administration [23,24]. Although colistin has shown significant activity against a wide

variety of gram-negative pathogens, its use was stopped in the 1970s because of its nephrotoxicity and neurotoxicity [25]. However, the emergence of MDR or carbapenem-resistant gram-negative bacterial pathogens and the lack of new antibiotics to treat them have led to the resurgence of colistin [26,27].

Colistin mediates bactericidal activity by interacting with the lipid A component of the lipopolysaccharide (LPS) present on gram-negative pathogens, including *A. baumannii* [28]. Because of an electrostatic interaction between the positively charged colistin on one side and phosphate groups of the negatively charged lipid A membrane on the other side, divalent cations such as Ca^{2+} and Mg^{2+} are displaced from the membrane lipids. This destabilizes LPS and, consequently, increases the permeability of the membrane, leading to outer membrane disruption and cell death [26]. Other action mechanisms of colistin have been proposed: endotoxin effect, inhibition of vital respiratory enzymes, and hydroxyl radical production [28,29].

Colistin exhibits bactericidal activity in a concentration-dependent manner against gram-negative bacteria, including *A. baumannii*, with a minimal post-antibiotic effect [30]. However, re-growth with time has frequently been observed [31], and the inoculum effect, a phenomenon of decreasing efficacy of an antibiotic with increasing bacterial density, has been reported [30]. Colistin has a relatively narrow *in vitro* bacteria-killing spectrum. It is active against gram-negative bacilli, such as *Acinetobacter* spp., *Pseudomonas aeruginosa*, *Escherichia coli*, *Klebsiella* spp., and *Enterobacter* spp. However, it has shown inactivity against some gram-negative bacilli, such as *Burkholderia cepacia*, *Proteus* spp., *Providencia* spp., and *Serratia* spp., as well as against gram-negative and gram-positive cocci, gram-positive bacilli, anaerobes, fungi, and parasites [32]. In addition, some *Acinetobacter* species, such as *A. seifertii* and *Acinetobacter colistiniresistens*, have exhibited very high colistin resistance rates or seem to be intrinsically resistant to it [3,4].

COLISTIN RESISTANCE

Colistin resistance in gram-negative bacteria is known to occur via several mechanisms. The main mechanism is the addition of a cationic group, such as 4-amino-4-deoxy-L-arabinose (L-Ara4N) or phosphoethanolamine (pEtN) to the lipid A moiety of LPS, which results in a decrease in the net negative charge of the bacterial outer membrane [33-37]. In most gram-negative bacteria, the addition of cationic groups is




Fig. 1. Overview of amino acid substitutions associated with colistin resistance in the polymyxin resistance (*pmr*) operon in *Acinetobacter baumannii*. Amino acid alterations are indicated with different colors, according to the references. Location of domains within the *pmr* operon was predicted using the SMART (simple, modular, architecture, research, tool) program (<http://smart.embl-heidelberg.de/>). fs, frameshift; Δ, deletion. ^{a)}On the top right of the letter indicates that an amino acid change found *in vitro* induced a colistin-resistant mutant.

regulated mainly by both PhoPQ and polymyxin resistance (*pmr*) PmrAB, which are two-component regulatory systems [28,38]. However, the *phoPQ* genes have not been found in the genome of *Acinetobacter* spp. [39]; thus, lipid A modification in *A. baumannii* is mediated by mutations in PmrAB [33,34,40-43]. Mutations in the *pmrA* or *pmrB* genes cause upregulation of the *pmrCAB* operon, leading to the synthesis and addition of pEtN, which is responsible for colistin resistance in *A. baumannii*. Amino acid alternations in PmrCAB of *A. baumannii* reported to date are presented in Fig. 1 [34,40-48]. As shown in Fig. 1, most amino acid substitutions associated with colistin resistance have been found in PmrB, a membrane-bound histidine kinase. However, it has not been verified experimentally if most variations are really responsible for colistin resistance in *A. baumannii*. Colistin-resistant mutants with no mutations in the *pmrA* and *pmrB* genes have also been identified, implying that the amino acid changes in the PmrAB two-component system are not essential for *A. baumannii* colistin resistance [41].

In addition to lipid A modification of LPS, loss of LPS has been reported to be associated with colistin resistance in *A.*

baumannii [49]. Alterations in the lipid A biosynthesis genes (*lpxA*, *lpxC*, and *lpxD*) by amino acid substitutions, deletions, or insertion of *ISAbal* are responsible for the loss of LPS [49,50]. A recent metabolomic study revealed that an LPS-deficient, colistin-resistant *A. baumannii* strain showed perturbation in specific amino acid and carbohydrate metabolites, particularly pentose phosphate pathway and TCA (tricarboxylic acid) cycle intermediates [37]. In addition, depletion of peptidoglycan metabolites was observed in LPS-deficient strains. Several studies have reported increased susceptibility to some antibiotics rather than polymyxins in LPS-deficient, colistin-resistant *A. baumannii* strains [51,52], which has been postulated to be due to an increase in the passive diffusion of antibiotics. Decreased virulence in LPS-deficient strains has also been observed, which is compared with no change in the virulence of colistin-resistant strains due to *pmrAB* mutations [44,53]. To date, colistin resistance through the loss of LPS has not been detected in bacteria other than *Acinetobacter* spp.

Other colistin resistance mechanisms have been suggested in other gram-negative bacteria: overproduction of the cap-

sule polysaccharide (CPS) and efflux pumps [54,55]. For CPS production, reduced production of CPS in colistin-resistant mutants was observed in *Klebsiella pneumoniae*, which is a contradictory finding [56]. While an efflux pump inhibitor, carbonyl cyanide 3-chlorophenylhydrazone (CCCP) increased colistin susceptibility in *A. baumannii*, other efflux pump inhibitors, including phenylalanine-arginine β -naphthylamide (PA β N) did not show such an effect [31]. Thus, the roles of CPS overproduction and efflux pumps in colistin resistance should be further investigated.

Unlike the chromosome-related colistin resistance mechanisms described above, the plasmid-borne resistance gene mobilized colistin resistance (*mcr-1*) has been recently reported from *E. coli* isolates in China [57]. Since the first report, *mcr-1*, which encodes pEtN transferase, has been detected in dozens of countries worldwide, including South Korea [58,59]. Although it has been reported in diverse bacterial species, such as *E. coli*, *K. pneumoniae*, *Enterobacter cloacae*, *Enterobacter aerogenes*, *Salmonella* spp., and *Shigella sonnei*, it has not been found in *Acinetobacter* spp. isolates [60]. However, a *mcr-1*-carrying plasmid could be introduced into *A. baumannii*, and reduced susceptibility to colistin was observed, highlighting the risk of horizontal transfer of colistin resistance in *A. baumannii* [61].

It is estimated that colistin preserves its activity against many gram-negative pathogens, including *Acinetobacter* spp. An antimicrobial susceptibility study based on worldwide collection during 2006 and 2009 exhibited that colistin

showed potent *in vitro* activities against *Acinetobacter* spp. (MIC₉₀, 1 mg/L; 98.6% susceptibility) [62]. Recent SENTRY Antimicrobial Surveillance Program data also show that more than 95% of *Acinetobacter* spp. isolates from Europe, China, and the United States are susceptible to colistin [63,64]. In South Korea, colistin resistance rates among *A. baumannii* isolates have been estimated to be 7.0% and 2.4% [4,8]. A recent study has also shown a colistin resistance rate of 8.6% among *Acinetobacter* spp. clinical isolates [65]. However, it did not delineate *Acinetobacter* spp. and may have overestimated the colistin resistance rate in *A. baumannii* because of high colistin resistance rates in other species of the Acb complex, *A. seifertii* and *A. pittii* [4,8]. While colistin resistance in *A. baumannii* seems to occur readily by simple mutation in both laboratories and patients [45,66], a genotyping study revealed that colistin-resistant *A. baumannii* isolates did not disseminate clonally [67].

COLISTIN DEPENDENCE

Several investigators have reported heteroresistance to colistin in *A. baumannii*, which has been supposed to cause the emergence of colistin resistance by exposure to colistin [68-70]. Heteroresistance is generally defined as a case in which subpopulations of antibiotic-susceptible bacteria show resistance to certain antibiotics [71]. The heteroresistant subpopulations survive at high antibiotic concentrations in a ratio of $\sim 10^{-6}$ in a population analysis profiling (PAP) or appear as dis-




Fig. 2. Results of the disc diffusion assay for the colistin-susceptible, colistin-resistant, and colistin-dependent phenotypes. H06-855R and H06-855D are the colistin-resistant and colistin-dependent mutants, respectively, that originated from the colistin-susceptible *Acinetobacter baumannii* strain H06-855. The colistin-dependent mutant was obtained from colonies that survived 10 mg/L of colistin during the population analysis. While the colistin-resistant mutant grew throughout the plate, irrespective of the colistin disc, the colistin-dependent mutant grew only around the colistin disc.

tinct colonies growing within the clear zone of inhibition in the disc or E-test assay [71].

Unusually, some surviving *A. baumannii* subpopulations at high colistin concentrations in PAP exhibit the colistin dependence phenomenon. That is, when surviving colonies at ≥ 8 mg/L colistin during PAP were plated on solid agar with discs of 10 mg colistin, the bacteria grew only near the disc (Fig. 2). Such colistin dependence was first identified in an *Acinetobacter* sp. isolate from a calcaneus bone specimen of a patient with calcaneal osteomyelitis and bacteremia by Hawley et al. [72] during a population analysis. It was the first report on colistin dependence, and they identified the isolate as *A. baumannii*-*A. calcoaceticus* because they did not identify it to the species level.

The antibiotic dependence phenomenon was first reported in vancomycin-dependent *Enterococcus faecalis* in 1994 [73]. Vancomycin dependence in enterococci has subsequently been identified [74-76]; it may not be rare and may occur regardless of the use of vancomycin [77]. Because vancomycin-dependent isolates lack ligase activity because of mutations in the D-alanine D-alanine ligase (*ddl*) gene encoding the D-Ala-D-Ala ligase protein, they require glycopeptide antibiotics for cell-wall synthesis [78]. Although linezolid-dependent *Staphylococcus epidermidis* and β -lactam-dependent *Staphylococcus saprophyticus* have been reported [79,80], antibiotic dependence has been rarely identified in gram-negative bacteria.

After Hawley et al. [72], Garcia-Quintanilla et al. [81] identified partial colistin dependence by using the E-test assay. They found that some LPS-deficient, colistin-resistant *A. baumannii* strains with mutations in *lpxA*, *lpxC*, and *lpxD* showed partial colistin dependence. However, colistin resistance through LPS modification due to mutations in the PmrAB did not convert into colistin dependence. Although they proposed the loss of LPS as a colistin dependence mechanism, they did not address why a colistin-resistant isolate with the loss of LPS converted into colistin dependence. Thus, the mechanism underlying colistin dependence in *A. baumannii* is unclear.

Recently, we reported the development of colistin dependence in clinical colistin-susceptible *A. baumannii* isolates after exposure to colistin [82]. In that study, development of colistin dependence was not rare; 32.9% of 149 colistin-susceptible isolates developed colistin dependence. Genotypic analyses revealed that colistin dependence originated from the corresponding susceptible parental isolates, and no evidence of clonal dissemination of the isolates that developed

colistin dependence was found. Colistin-dependent mutants have shown increased susceptibility to several antibiotics, such as carbapenems [72,81,82], which is the feature of LPS-deficient, colistin-resistant isolates [51,52]. Of note, patients with colistin-dependent strains have shown higher 3- and 7-day treatment failure than the patients without colistin-dependent strains [82]. Thus, the development of colistin-dependent mutants may have clinical significance, and it should be investigated. A recent study showed that the colistin-dependent phenotype may arise from the loss of LPS or defects in its structure, resulting from the disruption of LpxC [83]. In that study, transition of colistin dependence into colistin resistance was also demonstrated in the absence of antibiotic selection pressure [83].

CONCLUSION

The need for new antibiotics is growing in this era of antibiotic resistance; however, the development of new antibiotics, particularly for MDR gram-negative bacteria, has slowed down. Thus, the importance of older drugs, such as colistin, is increasing. However, the colistin resistance rate seems to be increasing, and information on the colistin resistance mechanism is limited. In addition to colistin resistance, abnormal phenomena such as colistin dependence have been found; however, there are few studies on colistin dependence. To cope with the antibiotic resistance era and use colistin effectively, a wide range of studies on colistin resistance and dependence should be performed.

CONFLICTS OF INTEREST

No potential conflict of interest relevant to this article was reported.

REFERENCES

1. Henry R. Etymologia: acinetobacter. *Emerg Infect Dis* 2013;19:841.
2. Bergogne-Berezin E, Towner KJ. *Acinetobacter* spp. as nosocomial pathogens: microbiological, clinical, and epidemiological features. *Clin Microbiol Rev* 1996;9:148-65.
3. Nemeč A, Radolfova-Krizova L, Maixnerova M, Sedo O. *Acinetobacter colistiniresistens* sp. nov. (formerly genomic species 13 sensu Bouvet and Jeanjean and genomic species 14 sensu Tjernberg and Ursing), isolated from human infections and characterized by intrinsic re-

- sistance to polymyxins. *Int J Syst Evol Microbiol* 2017;67:2134-41.
4. Park YK, Jung SI, Park KH, Kim DH, Choi JY, Kim SH, et al. Changes in antimicrobial susceptibility and major clones of *Acinetobacter calcoaceticus-baumannii* complex isolates from a single hospital in Korea over 7 years. *J Med Microbiol* 2012;61(Pt 1):71-9.
 5. Park KH, Shin JH, Lee SY, Kim SH, Jang MO, Kang SJ, et al. The clinical characteristics, carbapenem resistance, and outcome of *Acinetobacter* bacteremia according to genotype. *PLoS One* 2013;8:e65026.
 6. Wong D, Nielsen TB, Bonomo RA, Pantapalangkoor P, Luna B, Spellberg B. Clinical and pathophysiological overview of *Acinetobacter* infections: a century of challenges. *Clin Microbiol Rev* 2017;30:409-47.
 7. Dijkshoorn L, Nemec A, Seifert H. An increasing threat in hospitals: multidrug-resistant *Acinetobacter baumannii*. *Nat Rev Microbiol* 2007;5:939-51.
 8. Ko KS, Suh JY, Kwon KT, Jung SI, Park KH, Kang CI, et al. High rates of resistance to colistin and polymyxin B in subgroups of *Acinetobacter baumannii* isolates from Korea. *J Antimicrob Chemother* 2007;60:1163-7.
 9. Kim DH, Park YK, Choi JY, Ko KS. Identification of genetic recombination between *Acinetobacter* species based on multilocus sequence analysis. *Diagn Microbiol Infect Dis* 2012;73:284-6.
 10. Peleg AY, Seifert H, Paterson DL. *Acinetobacter baumannii*: emergence of a successful pathogen. *Clin Microbiol Rev* 2008;21:538-82.
 11. Perez F, Hujer AM, Hujer KM, Decker BK, Rather PN, Bonomo RA. Global challenge of multidrug-resistant *Acinetobacter baumannii*. *Antimicrob Agents Chemother* 2007;51:3471-84.
 12. Boucher HW, Talbot GH, Bradley JS, Edwards JE, Gilbert D, Rice LB, et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. *Clin Infect Dis* 2009;48:1-12.
 13. Willyard C. The drug-resistant bacteria that pose the greatest health threats. *Nature* 2017;543:15.
 14. Centres for Disease Control and Prevention (U.S.) Antibiotic resistance threats in the United States, 2013. Atlanta (GA): Centres for Disease Control and Prevention, U.S. Department of Health and Human Services; 2013.
 15. Yong D, Shin HB, Kim YK, Cho J, Lee WG, Ha GY, et al. Increase in the prevalence of carbapenem-resistant *Acinetobacter* isolates and ampicillin-resistant non-typhoidal salmonella species in Korea: a KONSAR Study conducted in 2011. *Infect Chemother* 2014;46:84-93.
 16. Chung DR, Song JH, Kim SH, Thamlikitkul V, Huang SG, Wang H, et al. High prevalence of multidrug-resistant nonfermenters in hospital-acquired pneumonia in Asia. *Am J Respir Crit Care Med* 2011;184:1409-17.
 17. Tankovic J, Legrand P, De Gatines G, Chemineau V, Brun-Buisson C, Duval J. Characterization of a hospital outbreak of imipenem-resistant *Acinetobacter baumannii* by phenotypic and genotypic typing methods. *J Clin Microbiol* 1994;32:2677-81.
 18. Korea Centers for Disease Control and Prevention (KCDC). KARMS (Korean Antimicrobial Resistance Monitoring System) 2015 Annual Report. Cheongju (KR): KCDC, Korea National Institute of Health; 2016.
 19. Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. *Clin Microbiol Infect* 2012;18:268-81.
 20. Nation RL, Li J. Colistin in the 21st century. *Curr Opin Infect Dis* 2009;22:535-43.
 21. Benedict RG, Langlykke AF. Antibiotic activity of *Bacillus polymyxa*. *J Bacteriol* 1947;54:24.
 22. Velkov T, Thompson PE, Nation RL, Li J. Structure: activity relationships of polymyxin antibiotics. *J Med Chem* 2010;53:1898-916.
 23. Bergen PJ, Li J, Rayner CR, Nation RL. Colistin methanesulfonate is an inactive prodrug of colistin against *Pseudomonas aeruginosa*. *Antimicrob Agents Chemother* 2006;50:1953-8.
 24. Nation RL, Velkov T, Li J. Colistin and polymyxin B: peas in a pod, or chalk and cheese? *Clin Infect Dis* 2014;59:88-94.
 25. Kelesidis T, Falagas ME. The safety of polymyxin antibiotics. *Expert Opin Drug Saf* 2015;14:1687-701.
 26. Li J, Nation RL, Turnidge JD, Milne RW, Coulthard K, Rayner CR, et al. Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections. *Lancet Infect Dis* 2006;6:589-601.
 27. Landman D, Georgescu C, Martin DA, Quale J. Polymyxins revisited. *Clin Microbiol Rev* 2008;21:449-65.
 28. Poirel L, Jayol A, Nordmann P. Polymyxins: antibacterial activity, susceptibility testing, and resistance mechanisms encoded by plasmids or chromosomes. *Clin Microbiol Rev* 2017;30:557-96.
 29. Sampson TR, Liu X, Schroeder MR, Kraft CS, Burd EM, Weiss DS. Rapid killing of *Acinetobacter baumannii* by polymyxins is mediated by a hydroxyl radical death path-

- way. *Antimicrob Agents Chemother* 2012;56:5642-9.
30. Tran TB, Velkov T, Nation RL, Forrest A, Tsuji BT, Bergen PJ, et al. Pharmacokinetics/pharmacodynamics of colistin and polymyxin B: are we there yet? *Int J Antimicrob Agents* 2016;48:592-7.
 31. Park YK, Ko KS. Effect of carbonyl cyanide 3-chlorophenylhydrazone (CCCP) on killing *Acinetobacter baumannii* by colistin. *J Microbiol* 2015;53:53-9.
 32. Falagas ME, Kasiakou SK. Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections. *Clin Infect Dis* 2005; 40:1333-41.
 33. Beceiro A, Llobet E, Aranda J, Bengoechea JA, Doumith M, Hornsey M, et al. Phosphoethanolamine modification of lipid A in colistin-resistant variants of *Acinetobacter baumannii* mediated by the pmrAB two-component regulatory system. *Antimicrob Agents Chemother* 2011;55:3370-9.
 34. Arroyo LA, Herrera CM, Fernandez L, Hankins JV, Trent MS, Hancock RE. The pmrCAB operon mediates polymyxin resistance in *Acinetobacter baumannii* ATCC 17978 and clinical isolates through phosphoethanolamine modification of lipid A. *Antimicrob Agents Chemother* 2011;55:3743-51.
 35. Park YK, Lee JY, Ko KS. Transcriptomic analysis of colistin-susceptible and colistin-resistant isolates identifies genes associated with colistin resistance in *Acinetobacter baumannii*. *Clin Microbiol Infect* 2015;21:765.
 36. Qureshi ZA, Hittle LE, O'Hara JA, Rivera JI, Syed A, Shields RK, et al. Colistin-resistant *Acinetobacter baumannii*: beyond carbapenem resistance. *Clin Infect Dis* 2015;60: 1295-303.
 37. Maifiah MH, Cheah SE, Johnson MD, Han ML, Boyce JD, Thamlikitkul V, et al. Global metabolic analyses identify key differences in metabolite levels between polymyxin-susceptible and polymyxin-resistant *Acinetobacter baumannii*. *Sci Rep* 2016;6:22287.
 38. Olaitan AO, Morand S, Rolain JM. Mechanisms of polymyxin resistance: acquired and intrinsic resistance in bacteria. *Front Microbiol* 2014;5:643.
 39. Adams MD, Goglin K, Molyneaux N, Hujer KM, Lavender H, Jamison JJ, et al. Comparative genome sequence analysis of multidrug-resistant *Acinetobacter baumannii*. *J Bacteriol* 2008;190:8053-64.
 40. Adams MD, Nickel GC, Bajaksouzian S, Lavender H, Murthy AR, Jacobs MR, et al. Resistance to colistin in *Acinetobacter baumannii* associated with mutations in the PmrAB two-component system. *Antimicrob Agents Chemother* 2009;53:3628-34.
 41. Park YK, Choi JY, Shin D, Ko KS. Correlation between overexpression and amino acid substitution of the PmrAB locus and colistin resistance in *Acinetobacter baumannii*. *Int J Antimicrob Agents* 2011;37:525-30.
 42. Lesho E, Yoon EJ, McGann P, Snesrud E, Kwak Y, Milillo M, et al. Emergence of colistin-resistance in extremely drug-resistant *Acinetobacter baumannii* containing a novel pmrCAB operon during colistin therapy of wound infections. *J Infect Dis* 2013;208:1142-51.
 43. Choi MJ, Ko KS. Mutant prevention concentrations of colistin for *Acinetobacter baumannii*, *Pseudomonas aeruginosa* and *Klebsiella pneumoniae* clinical isolates. *J Antimicrob Chemother* 2014;69:275-7.
 44. Beceiro A, Moreno A, Fernandez N, Vallejo JA, Aranda J, Adler B, et al. Biological cost of different mechanisms of colistin resistance and their impact on virulence in *Acinetobacter baumannii*. *Antimicrob Agents Chemother* 2014; 58:518-26.
 45. Choi HJ, Kil MC, Choi JY, Kim SJ, Park KS, Kim YJ, et al. Characterisation of successive *Acinetobacter baumannii* isolates from a deceased haemophagocytic lymphohistiocytosis patient. *Int J Antimicrob Agents* 2017;49:102-6.
 46. Rolain JM, Diene SM, Kempf M, Gimenez G, Robert C, Raoult D. Real-time sequencing to decipher the molecular mechanism of resistance of a clinical pan-drug-resistant *Acinetobacter baumannii* isolate from Marseille, France. *Antimicrob Agents Chemother* 2013;57:592-6.
 47. Snitkin ES, Zelazny AM, Gupta J; NISC Comparative Sequencing Program, Palmore TN, Murray PR, et al. Genomic insights into the fate of colistin resistance and *Acinetobacter baumannii* during patient treatment. *Genome Res* 2013;23:1155-62.
 48. Kim Y, Bae IK, Lee H, Jeong SH, Yong D, Lee K. In vivo emergence of colistin resistance in *Acinetobacter baumannii* clinical isolates of sequence type 357 during colistin treatment. *Diagn Microbiol Infect Dis* 2014;79:362-6.
 49. Moffatt JH, Harper M, Harrison P, Hale JD, Vinogradov E, Seemann T, et al. Colistin resistance in *Acinetobacter baumannii* is mediated by complete loss of lipopolysaccharide production. *Antimicrob Agents Chemother* 2010; 54:4971-7.
 50. Moffatt JH, Harper M, Adler B, Nation RL, Li J, Boyce JD. Insertion sequence ISAb11 is involved in colistin resistance and loss of lipopolysaccharide in *Acinetobacter baumannii*. *Antimicrob Agents Chemother* 2011;55:3022-4.
 51. Li J, Nation RL, Owen RJ, Wong S, Spelman D, Franklin C.

- Antibiograms of multidrug-resistant clinical *Acinetobacter baumannii*: promising therapeutic options for treatment of infection with colistin-resistant strains. *Clin Infect Dis* 2007;45:594-8.
52. Mendes RE, Fritsche TR, Sader HS, Jones RN. Increased antimicrobial susceptibility profiles among polymyxin-resistant *Acinetobacter baumannii* clinical isolates. *Clin Infect Dis* 2008;46:1324-6.
 53. Vila-Farres X, Ferrer-Navarro M, Callarisa AE, Marti S, Espinal P, Gupta S, et al. Loss of LPS is involved in the virulence and resistance to colistin of colistin-resistant *Acinetobacter nosocomialis* mutants selected in vitro. *J Antimicrob Chemother* 2015;70:2981-6.
 54. Llobet E, Tomas JM, Bengoechea JA. Capsule polysaccharide is a bacterial decoy for antimicrobial peptides. *Microbiology* 2008;154(Pt 12):3877-86.
 55. Srinivasan VB, Rajamohan G. KpnEF, a new member of the *Klebsiella pneumoniae* cell envelope stress response regulon, is an SMR-type efflux pump involved in broad-spectrum antimicrobial resistance. *Antimicrob Agents Chemother* 2013;57:4449-62.
 56. Choi MJ, Ko KS. Loss of hypermucoviscosity and increased fitness cost in colistin-resistant *Klebsiella pneumoniae* sequence type 23 strains. *Antimicrob Agents Chemother* 2015;59:6763-73.
 57. Liu YY, Wang Y, Walsh TR, Yi LX, Zhang R, Spencer J, et al. Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: a microbiological and molecular biological study. *Lancet Infect Dis* 2016;16:161-8.
 58. Lim SK, Kang HY, Lee K, Moon DC, Lee HS, Jung SC. First detection of the *mcr-1* gene in *Escherichia coli* isolated from livestock between 2013 and 2015 in South Korea. *Antimicrob Agents Chemother* 2016;60:6991-3.
 59. Kim ES, Chong YP, Park SJ, Kim MN, Kim SH, Lee SO, et al. Detection and genetic features of MCR-1-producing plasmid in human *Escherichia coli* infection in South Korea. *Diagn Microbiol Infect Dis* 2017;89:158-60.
 60. Jeannot K, Bolard A, Plesiat P. Resistance to polymyxins in Gram-negative organisms. *Int J Antimicrob Agents* 2017;49:526-35.
 61. Liu YY, Chandler CE, Leung LM, McElheny CL, Mettuss RT, Shanks RMQ, et al. Structural modification of lipopolysaccharide conferred by *mcr-1* in gram-negative ESKAPE pathogens. *Antimicrob Agents Chemother* 2017;61.
 62. Gales AC, Jones RN, Sader HS. Contemporary activity of colistin and polymyxin B against a worldwide collection of Gram-negative pathogens: results from the SENTRY Antimicrobial Surveillance Program (2006-09). *J Antimicrob Chemother* 2011;66:2070-4.
 63. Sader HS, Farrell DJ, Flamm RK, Jones RN. Antimicrobial susceptibility of Gram-negative organisms isolated from patients hospitalized in intensive care units in United States and European hospitals (2009-2011). *Diagn Microbiol Infect Dis* 2014;78:443-8.
 64. Flamm RK, Nichols WW, Sader HS, Farrell DJ, Jones RN. In vitro activity of ceftazidime/avibactam against Gram-negative pathogens isolated from pneumonia in hospitalised patients, including ventilated patients. *Int J Antimicrob Agents* 2016;47:235-42.
 65. Park GE, Kang CI, Cha MK, Cho SY, Seok H, Lee JH, et al. Bloodstream infections caused by *Acinetobacter* species with reduced susceptibility to tigecycline: clinical features and risk factors. *Int J Infect Dis* 2017;62:26-31.
 66. Lee JY, Choi MJ, Choi HJ, Ko KS. Preservation of acquired colistin resistance in gram-negative bacteria. *Antimicrob Agents Chemother* 2015;60:609-12.
 67. Park YK, Jung SI, Park KH, Cheong HS, Peck KR, Song JH, et al. Independent emergence of colistin-resistant *Acinetobacter* spp. isolates from Korea. *Diagn Microbiol Infect Dis* 2009;64:43-51.
 68. Li J, Rayner CR, Nation RL, Owen RJ, Spelman D, Tan KE, et al. Heteroresistance to colistin in multidrug-resistant *Acinetobacter baumannii*. *Antimicrob Agents Chemother* 2006;50:2946-50.
 69. Hawley JS, Murray CK, Jorgensen JH. Colistin heteroresistance in *Acinetobacter* and its association with previous colistin therapy. *Antimicrob Agents Chemother* 2008;52:351-2.
 70. Yau W, Owen RJ, Poudyal A, Bell JM, Turnidge JD, Yu HH, et al. Colistin hetero-resistance in multidrug-resistant *Acinetobacter baumannii* clinical isolates from the Western Pacific region in the SENTRY antimicrobial surveillance programme. *J Infect* 2009;58:138-44.
 71. El-Halfawy OM, Valvano MA. Antimicrobial heteroresistance: an emerging field in need of clarity. *Clin Microbiol Rev* 2015;28:191-207.
 72. Hawley JS, Murray CK, Jorgensen JH. Development of colistin-dependent *Acinetobacter baumannii*-*Acinetobacter calcoaceticus* complex. *Antimicrob Agents Chemother* 2007;51:4529-30.
 73. Fraimow HS, Jungkind DL, Lander DW, Delso DR, Dean JL. Urinary tract infection with an *Enterococcus faecalis* isolate that requires vancomycin for growth. *Ann Intern*

- Med 1994;121:22-6.
74. Van Bambeke F, Chauvel M, Reynolds PE, Fraimow HS, Courvalin P. Vancomycin-dependent *Enterococcus faecalis* clinical isolates and revertant mutants. *Antimicrob Agents Chemother* 1999;43:41-7.
75. Kirkpatrick BD, Harrington SM, Smith D, Marcellus D, Miller C, Dick J, et al. An outbreak of vancomycin-dependent *Enterococcus faecium* in a bone marrow transplant unit. *Clin Infect Dis* 1999;29:1268-73.
76. Tambyah PA, Marx JA, Maki DG. Nosocomial infection with vancomycin-dependent enterococci. *Emerg Infect Dis* 2004;10:1277-81.
77. Hwang K, Sung H, Namgoong S, Yoon NS, Kim MN. Microbiological and epidemiological characteristics of vancomycin-dependent enterococci. *Korean J Lab Med* 2009; 29:299-306.
78. Kuo SF, Huang SP, Lee CH. Vancomycin-dependent *Enterococcus faecium* can easily be obscured. *J Microbiol Immunol Infect* 2016.
79. Worthington T, White J, Lambert P, Adlakha S, Elliott T. Beta-lactam-dependent coagulase-negative staphylococcus associated with urinary-tract infection. *Lancet* 1999;354:1097.
80. Pournaras S, Ntokou E, Zarkotou O, Ranellou K, Themeli-Digalaki K, Stathopoulos C, et al. Linezolid dependence in *Staphylococcus epidermidis* bloodstream isolates. *Emerg Infect Dis* 2013;19:129-32.
81. Garcia-Quintanilla M, Carretero-Ledesma M, Moreno-Martinez P, Martin-Pena R, Pachon J, McConnell MJ. Lipopolysaccharide loss produces partial colistin dependence and collateral sensitivity to azithromycin, rifampicin and vancomycin in *Acinetobacter baumannii*. *Int J Antimicrob Agents* 2015;46:696-702.
82. Hong YK, Lee JY, Wi YM, Ko KS. High rate of colistin dependence in *Acinetobacter baumannii*. *J Antimicrob Chemother* 2016;71:2346-8.
83. Lee JY, Chung ES, Ko KS. Transition of colistin dependence into colistin resistance in *Acinetobacter baumannii*. *Sci Rep* 2017;7:14216.